The impact of multiple sclerosis (MS) on cognitive function is widely recognized; roughly half of adults with MS are affected. Cognitive decline can be seen as early as following an initial demyelinating event (clinical isolated syndrome), but with significantly more deterioration in progressive MS patients. Cognitive impairment (CI) and fatigue are the main barriers to maintenance of employment 1 and limit independence.
Cognitive assessment in MS
Cognitive function is most commonly assessed using conventional neuropsychological tests known to be sensitive to the disease. As a field, we continue to strive toward a narrower scope of recommended tests to achieve cost-effective evaluation. way to assess only episodic memory with the California Verbal Learning Test and Brief Visuospatial Memory Test Revised, and cognitive processing speed using the Symbol Digit Modalities Test (SDMT). A recent review and consortium opinion suggests that the SDMT measure of processing speed is most central to MS CI research, supports its reliability, validity and sensitivity to MS, and proposes that a change in SDMT score of 4 points, or 10%, is clinically meaningful. 5 
Cognitive decline and MS disease activity
Cognitive decline occurs as a result of gradual progression related to neurodegeneration, or more transient changes related to acute (i.e. relapses) disease activity. The former is well established in longitudinal studies dating to the early 1990s. The latter is a more recent observation and is particularly relevant to the ever-increasing efficacy of disease-modifying therapies (DMTs). STRATA, 6 an observational safety study of natalizumab, showed that SDMT scores declined in patients undergoing relapse, compared to their stable and steadily improving counterparts. The report was replicated in a controlled, prospective study of 24 relapsing and 24 non-relapsing MS patients. 7 All were examined at the time of relapse, before corticosteroid treatment, and again 3 months later. "Relapsers" were suspected of CI on the basis of clinician or observer impression, that is, a diagnosed clinical relapse with cognitive decline. Pardini et al. 8 attempted to validate the concept by examining patients free of relapse, and having no clinical change by expanded disability status scale (EDSS), but at least a 4-point decline on SDMT from baseline. These patients with an "isolated cognitive relapse" also evidenced gadolinium enhancement on MRI concordant with the SDMT decline. Importantly, in all three studies, SDMT declines were followed by partial, not full, recovery of function.
Therefore, we argue that progressive decline in cognition or acute/rapid cognitive changes in MS should be included in the spectrum of disease activity and A decline in cognitive function should lead to a change in disease-modifying therapy -Yes thereby part of the definition of clinical stability of disease defined as no evidence of disease activity (NEDA). In a prospective study of relapsing-remitting multiple sclerosis (RRMS) patients, 30.8% had NEDA after 2 years of follow-up but 58.3% of those patients still had worsening in ⩾ 2 cognitive domains with 25% of NEDA classified patients having a meaningful decline on SDMT. 9 Randomized controlled studies which included cognitive outcome measures One caveat might be that evidence for impact of DMTs on cognitive outcome measures is limited. We note, however, that the first multicenter clinical trial in MS to prospectively assess neuropsychiatric outcomes with intramuscular weekly Interferon beta-1a showed delayed time to onset of sustained deterioration on cognitive processing speed and learning measures. As the neurocognitive battery was arduous and did not lead to an indication for cognition, the cognitive domain was largely ignored in phase 3 trials until the recent reemergence of the SDMT, with alternate forms. In the most recent meeting of the American Academy of Neurology (AAN), analyses of the effects of ocrelizumab and siponimod showed a statistically significant and clinical meaningful benefit. 10,11
Conclusion
If we accept that cognitive deficits in MS patients, or cognitive decline from baseline, reflect cerebral disease, then it would seem self-evident that this sign/ symptom merits clinical attention as would any other indication of disease activity. Our position is that neuropsychological impairment reflects cerebral disease in MS, which is "disease activity," and as such merits clinical attention when drugs are considered that may mitigate MS disease activity. Recent 2018 AAN recommendations for switching therapies considered suboptimal response to DMTs based on published clinical trials. 12 As more clinical trial data with SDMT are presented, we are in a position to interpret SDMT decline as evidence of suboptimal response and in turn consider a change in DMT.
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